J. Thirlwell

2.6k total citations · 1 hit paper
17 papers, 1.9k citations indexed

About

J. Thirlwell is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Immunology and Allergy. According to data from OpenAlex, J. Thirlwell has authored 17 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Physiology and 8 papers in Immunology and Allergy. Recurrent topics in J. Thirlwell's work include Asthma and respiratory diseases (11 papers), Allergic Rhinitis and Sensitization (8 papers) and Respiratory and Cough-Related Research (4 papers). J. Thirlwell is often cited by papers focused on Asthma and respiratory diseases (11 papers), Allergic Rhinitis and Sensitization (8 papers) and Respiratory and Cough-Related Research (4 papers). J. Thirlwell collaborates with scholars based in United Kingdom, Switzerland and United States. J. Thirlwell's co-authors include Giovanni Della Cioppa, M. Solèr, H. Fox, Roland Buhl, Robert G. Townley, J S O′Brien, Jonathan Matz, Niroo Gupta, Stephen T. Holgate and Jan Lötvall and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Allergy and Clinical Immunology and Annals of Oncology.

In The Last Decade

J. Thirlwell

16 papers receiving 1.8k citations

Hit Papers

The anti-IgE antibody omalizumab reduces exacerbations an... 2001 2026 2009 2017 2001 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
    2001 647 citations M. Solèr, Jonathan Matz et al. European Respiratory Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Thirlwell United Kingdom 12 1.7k 1.3k 1.0k 243 91 17 1.9k
Martin Blogg United Kingdom 13 2.3k 1.3× 1.7k 1.3× 1.4k 1.3× 285 1.2× 166 1.8× 36 2.5k
Lynn E. Katz United States 3 1.6k 0.9× 1.2k 0.9× 378 0.4× 429 1.8× 54 0.6× 8 1.8k
Sandhia Ponnarambil United States 7 1.3k 0.8× 906 0.7× 365 0.4× 372 1.5× 73 0.8× 30 1.5k
Alexandra M. Nanzer United Kingdom 13 531 0.3× 451 0.4× 139 0.1× 102 0.4× 26 0.3× 26 724
Katerina Samara Greece 15 348 0.2× 805 0.6× 50 0.0× 102 0.4× 10 0.1× 35 1.0k
A. Prudhomme France 12 318 0.2× 336 0.3× 119 0.1× 79 0.3× 10 0.1× 31 508
P. Pantelidis United Kingdom 12 254 0.1× 866 0.7× 21 0.0× 87 0.4× 3 0.0× 14 1.0k
J Mooney United Kingdom 7 165 0.1× 537 0.4× 20 0.0× 93 0.4× 11 0.1× 11 730
H H Chng Singapore 13 65 0.0× 45 0.0× 117 0.1× 164 0.7× 37 0.4× 25 668
Jens Helby Denmark 9 124 0.1× 66 0.1× 12 0.0× 70 0.3× 13 0.1× 21 425

Countries citing papers authored by J. Thirlwell

Since Specialization
Citations

This map shows the geographic impact of J. Thirlwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Thirlwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Thirlwell more than expected).

Fields of papers citing papers by J. Thirlwell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Thirlwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Thirlwell. The network helps show where J. Thirlwell may publish in the future.

Co-authorship network of co-authors of J. Thirlwell

This figure shows the co-authorship network connecting the top 25 collaborators of J. Thirlwell. A scholar is included among the top collaborators of J. Thirlwell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Thirlwell. J. Thirlwell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Youn, Sang Woong, Seong Jin Jo, Chul Jong Park, et al.. (2024). Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo‐controlled, double‐blinded study. The Journal of Dermatology. 51(11). 1392–1403.
2.
3.
Robertson, J.F.R., Kwok‐Leung Cheung, Shinzaburo Noguchi, et al.. (2018). Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer. European Journal of Cancer. 94. 206–215. 14 indexed citations
4.
Cheung, Kwok‐Leung, Shinzaburo Noguchi, Zhimin Shao, et al.. (2017). Health-related quality of life from a phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced breast cancer (FALCON).. Journal of Clinical Oncology. 35(15_suppl). 1048–1048. 2 indexed citations
5.
Malorni, Luca, Chiara Biagioni, J. Thirlwell, et al.. (2014). Efficacy of Fulvestrant According to Duration and Type of Adjuvant Endocrine Treatment, in Metastatic Breast Cancer Patients Enrolled in the Confirm Trial. Annals of Oncology. 25. i8–i8. 1 indexed citations
6.
Braunstahl, Gert‐Jan, et al.. (2011). Uncontrolled persistent allergic asthma in practice: eXpeRience registry baseline characteristics. Current Medical Research and Opinion. 27(4). 761–767. 16 indexed citations
7.
Molimard, Mathiéu, Roland Buhl, Robert Niven, et al.. (2010). Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: Real-life data. Respiratory Medicine. 104(9). 1381–1385. 65 indexed citations
8.
Molimard, Mathiéu, Robert Niven, Roland Buhl, et al.. (2009). European Real-Life Experience Of Omalizumab (Xolair) And Maintenance Oral Corticosteroid Use In Patients With Severe Persistent Allergic Asthma. Journal of Allergy and Clinical Immunology. 123(2). S156–S156. 2 indexed citations
9.
Vogelmeier, Claus, Péter Kardos, Sergio Harari, et al.. (2008). Formoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month study. Respiratory Medicine. 102(11). 1511–1520. 140 indexed citations
10.
Neder, J. Alberto, Jonathan Fuld, Tim Overend, et al.. (2007). Effects of formoterol on exercise tolerance in severely disabled patients with COPD. Respiratory Medicine. 101(10). 2056–2064. 40 indexed citations
11.
Holgate, Stephen T., А. Г. Чучалин, Jean‐Louis Hébert, et al.. (2004). Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clinical & Experimental Allergy. 34(4). 632–638. 406 indexed citations
12.
Buhl, Roland, G. Hanf, M. Solèr, et al.. (2002). The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. European Respiratory Journal. 20(5). 1088–1094. 124 indexed citations
13.
Buhl, Roland, M. Solèr, Jonathan Matz, et al.. (2002). Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. European Respiratory Journal. 20(1). 73–78. 162 indexed citations
14.
Chung, Kian Fan, Stephen T. Holgate, John S. O’Brien, Howard Fox, & J. Thirlwell. (2002). Inhaled corticosteroid dose-reducing effect of omalizumab in patients with controlled, severe asthma according to usage of inhaled long-acting beta-agonists. Journal of Allergy and Clinical Immunology. 109(1). S239–S239. 3 indexed citations
15.
Solèr, M., Jonathan Matz, Robert G. Townley, et al.. (2001). The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. European Respiratory Journal. 18(2). 254–261. 647 indexed citations breakdown →
16.
Ädelroth, E, S. Rak, Tari Haahtela, et al.. (2000). Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen–induced seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology. 106(2). 253–259. 240 indexed citations
17.
Cífková, Renata, Jan Peleška, J Hradec, et al.. (1998). Valsartan and atenolol in patients with severe essential hypertension. Journal of Human Hypertension. 12(8). 563–567. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin Blogg Breakdown of academic impact, for papers by Lynn E. Katz Breakdown of academic impact, for papers by Sandhia Ponnarambil Breakdown of academic impact, for papers by Alexandra M. Nanzer Breakdown of academic impact, for papers by Katerina Samara Breakdown of academic impact, for papers by A. Prudhomme Breakdown of academic impact, for papers by P. Pantelidis Breakdown of academic impact, for papers by J Mooney Breakdown of academic impact, for papers by H H Chng Breakdown of academic impact, for papers by Jens Helby
Rankless by CCL
2026